

NCI SBIR AND YOUR STATE:

MARYLAND



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$66.7 million** in funding across **46 Phase II SBIR/STTR grants** to small businesses in Maryland. The following economic impact estimates quantify the program's contributions to the state's economy:

	\$139.1M	IN TOTAL DIRECT SALES
	\$444.3M	IN TOTAL ECONOMIC IMPACT
	1.8K	JOBS CREATED
	\$17.7M	IN STATE & LOCAL TAXES COLLECTED
	16	COMPANIES WITH SALES

**These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Maryland: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$185.8M in funding across all grants to oncology-focused small businesses in the state.*

Success stories include:

BENEVIR BIOPHARM, INC.

Benevir received SBIR awards to conduct early-stage research for its oncolytic immunotherapy technologies that are designed to infect and destroy cancer cells. Benevir entered a \$1 billion acquisition agreement with Janssen in 2018 to support the company's immune-oncology portfolio.

ONCOSPAC, INC.

John's Hopkins University startup Oncospace used SBIR funding to develop its system for radiation therapy treatment planning guidance. The technology has received multiple 510k clearances from the FDA and was acquired by Sun Nuclear in April 2025.

The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to ncisbir@mail.nih.gov.